TRIO MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, CHEM Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181 E-mail: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 20210338 2021; 29th June 2021

To **BSE** Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001. Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Submission of Audited Financial Results for the Quarter and Year ended 31st March 2021

We refer to our letter dated 15th June 2021 on the captioned subject.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, In this subject, we wish to inform you that the Board of Director of the Company at its meeting held today i.e. Tuesday, 29th June 2021 have inter-alia considered and approved the Audited Financial Results of the Company for the quarter/year ended 31st March, 2021 duly reviewed by the Audit Committee.

The said financial results, duly signed by the Director & CEO of the company along with the statutory auditor's report with unmodified opinion thereon are enclosed for your perusal and records. A declaration is given in compliance to Regulation 33(3)d of the SEBI (LODR) Regulation, 2015 as amended by the SEBI (LODR) (Amendment) Regulation, 2016 vide notification no. CIR/CFD/CMD/56/2016 dated May 27, 2016, and notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016, is also enclosed.

Also, informed that the audited financial results in prescribed format will be published in "Free Press Journal" and "Navshakti" newspaper, as required. Please take the same in you record.

Thanking you, Yours faithfully, For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA **DIRECTOR & CEO** DIN: 00312369 Encl.: as above



Pune Address : 123, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 • T : 020 4906 7177 E : info@kdg.co.in • W : www.kdg.co.in

# Independent Auditor's Report on the Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

#### To,

#### The Board of Directors of Triochem Products Limited

#### Opinion

We have audited the accompanying statement of Financial Results of Triochem Products Limited ("the company") for the quarter ended March 31, 2021 and the year to date statement for the period from April 01, 2020 to March 31, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these Financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information for the quarter ended March 31, 2021 as well as the year to date statement for the period from April 01, 2020 to March 31, 2021.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Management's Responsibilities for the Financial Results

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation of these Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard

#### Kanu Doshi Associates LLP

prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statement or, if such disclosures are inadequate, to

modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

 Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### **Other Matters**

The annual financial results include the results for the quarter ended 31 March 2021 being the balancing figures between the audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year.

For Kanu Doshi Associates LLP Chartered Accountants Firm Registration No: 104746W/W100096

KUNAL SUMANT VAKHARIA Digitally signed by KUNAL SUMANT VAKHARIA Date: 2021.06.29 15:47:40 +05'30'

Kunal Vakharia

Partner Membership No: 148916 UDIN: 21148916AAAAFD5465 SOUTHER CHARTE

Place: Mumbai Date: June 29, 2021

#### **TRIO** MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, CHEM Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181 E-mail: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 20210339 2021; 29th June 2021

To **BSE** Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001. Security Code No. 512101 - ISIN No.: INE331E01013

Dear Sir / Madam,

## Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements), Regulation 2015

The Board of Directors of the Company at its meeting held on 29th June, 2021 has approved the Audited Financial Results of the Company for the year ended 31st March, 2021 and we hereby declare that the Statutory Auditors of the Company, M/s. Kanu Doshi Associates LLP., Chartered Accountants, (FRN: 104746W/W100096) have issued an Audit Report with unmodified opinion thereon.

This declaration is issued in compliance with the provisions of the Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) (Amendment), Regulation 2016 vide notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

The Declaration may kindly be taken on your records.

## For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA **DIRECTOR & CEO** DIN: 00312369



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



	TRIOCHEM PRODUC	TS LIMITED				
	Registered Office: Sambava Chambers, 4th Floor	, Sir P. M. Roa	d, Fort, Mumba	ai - 400 001		
	website: www.triochen	products.com	i i			
	CIN: L24249MH1972	PLC015544				
	AUDITED FINANCIAL RESULTS FOR THE QUART	ER AND YEAR	ENDED MARC	H 31, 2021		
					(Rs. in lakh	s) Except EF
Sr	Particulars		Quarter Ended	ĵ.	Year Ended	
No		MARCH 31,	DECEMBER	MARCH 31,	MARCH 31, MARCH 3	
		2021	31, 2020	2020	2021	2020
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		(Refer Note		(Refer Note		
		No. 5)		No. 5)		
	Income					
	(a) Revenue from Operations	773.48	394.50	1,147.66	1,393.84	2,003.1
	(b) Other income	7.54	0.16	33.38	13.38	46.6
	Total Income from operations	781.02	394.66	1,181.04	1,407.22	2,049.8
	Expenses:		07100	-,	-,,	_,,.
	(a) Cost of materials consumed	0.33	(0.00)	544.16	644.87	968.8
	(b) Purchase of stock-in-trade	602.73	(0.00)	32.77	602.73	37.5
	(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	125.29	360.19	251.69	13.41	354.6
	(d) Employee benefits expenses	16.39	16.74	30.41	66.91	82.3
	(c) Finance costs	1.37	2.47	5.78	10.90	22.9
	(f) Depreciation and amortisation expense	3.54	3.46	4.11	13.88	16.6
	(g) Other expenses	37.41	21.40	26.64	112.64	111.5
	Total Expenses	787.06	404.26	895.56	1,465.33	1,594.6
	Profit / (Loss) from ordinary activities before exceptional items (1-2)	(6.04)	(9.60)	285.48	(58.11)	455.1
	Exceptional items	-	-			-
	Profit / (Loss) before tax (3 +/- 4)	(6.04)	(9.60)	285.48	(58.11)	455.1
	Tax expense					
	- Current tax	(0.77)	(0.00)	73.31	(0.75)	117.3
	- Deferred tax	0.32	(2.42)	(0.63)	(12.66)	(2.4
	Total Tax expenses	(0.45)	(2.42)	72.68	(13.41)	114.9
	Profit / (Loss) for the period (5 +/- 6)	(5.59)	(7.18)	212.80	(44.70)	340.2
	Other comprehensive income, net of income tax					
	A. (i) Items that will be reclassified to profit or Loss	-				
	(ii) Income tax relating to items that will be reclassified to profit or loss					
	B. (i) Items that will not be reclassified to profit or Loss	(1.82)	0.43	0.02	(2.34)	(0.3
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.46	(0.11)	(0.00)	0.59	0.0
	Total Other comprehensive income, net of income tax	(1.36)	0.32	0.02	(1.75)	(0.2
	Total Comprehensive income for the period (8 +/- 7)	(6.95)	(6.86)	212.82	(46.45)	340.0
	some comprehensive meaner for the period (0 +/- /)	(0.73)	(0.00)	212.02	(10.13)	540.0
	Paid-up equity share capital (Face value of Rs10/- per share )	24.50	24.50	24.50	24.50	24.5
	Reserve excluding Revalution Reserves as per balance sheet of previous accounting year				1,146.69	1,193.1
	Earning per share (EPS) (of Rs. 10/- each ) (not annualised)					
	Basic / Diluted EPS	(2.28)	(2.93)	86.86	(18.25)	138.8



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



	STATEMENT OF AUDITED ASSETS AND LIABILITIES AS AT MAR	CH 31, 2021			
(Rs.in lak					
Sr	Particulars	As at	As at		
No		March 31, 2021	March 31, 2020		
		Audited	Audited		
1	ASSETS				
1	Non - Current Assets				
	(a) Property, plant and equipment	86.39	97.5		
	(b) Capital work - in - progress	3.24	3.24		
	(c) Investment property	7.72	8.1		
	(d) Financial assets				
	(i) Other financial assets	7.32	7.3		
	(c) Deferred tax assets (Net)	3.92			
	(f) Other non - current tax assets	0.71	7.20		
	(g) Other non - current assets	0.87	1.1		
	Sub total - Non - Current Assets	110.17	124.6		
2	Current Assets	11011/	12110		
Ĩ	(a) Inventories	85.36	155.4		
	(b) Financial assets	09.50	1)).1		
	(i) Trade receivables	139.06	1,239.8		
	(ii) Cash and cash equivalents	819.72	55.3		
	(ii) Other financial assets	0.65	507 I.C.		
	(c) Other tax assets (net)	51000.75	0.5		
	(d) Other current assets	33.17			
	(d) Other current assets Sub total - Current Assets	22.07	85.8		
	Total - Assets	1,100.03 1,210.20	1,537.0		
	Total - Assets	1,210.20	1,661.6		
в	EQUITY AND LIABILITIES				
,	EQUITY				
		24.50	24.5		
	(a) Equity share capital				
	(b) Other Equity	1,146.69	1,193.1		
	Total - Equity LIABILITIES	1,171.19	1,217.6		
1	Non Current Liabilities				
	(a) Deferred tax liabilities (Net)		9.3		
	Sub total - Non- Current Liabilities		9.3		
2	Current liabilities				
	(a) Financial liabilities				
	(i) Borrowings		250.3		
	(ii) Trade payables	32.44	74.0		
	(b) Other financial liabilities	•	13.9		
	(c) Other current liabilities	0.93	79.8		
	(c) Provisions	5.64	9.0		
	(d) Current tax liabilities (Net)		7.5		
	Sub- total - Current Liabilities	39.01	434.7		
	Total - Liabilities	39.01	444.0		
	Total - Equity and Liabilities	1,210.20	1,661.6		



Г

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. <u>Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com</u> <u>Website: www.triochemproducts.com</u> Corporate Identity Number: L24249MH1972PLC015544



#### CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2021

			(Rs.in lakhs)		
	Particulars		Year Ended		
		March 31,	March 31,		
		2021	2020		
		Audited	Audited		
	CASH FLOW FROM OPERATING ACTIVITIES	100000			
	Net Profit before tax and Extraordinary Items	(58.11)	455.18		
	Adjustment for:				
	Depreciation / Amortisation	13.88	16.68		
	Interest Income	(2.64)	(0.66		
	Reclassification of remeasurement of employee benefits	(2.34)	(0.30		
	Interest Expenses	10.89	20.06		
	Investment Expenses	0.04	0.05		
	Sundry balance Off	(5.65)	(0.00		
	Operating Profit before Working Capital Changes	(43.93)	491.01		
	Adjustments for Working Capital Changes				
	Increase/Decrease in Assets	64.10	(33.08		
	Changes in Inventories	70.05	802.03		
	Increase/Decrease Trade Receivable	1,100.83	(906.88		
	Increase/Decrease in other financial and non-financial assets	18 - I			
	Increase/Decrease Trade payables	(41.58)	39.88		
	Increase/Decrease in other financial and non-financial liabilities	(13.93)	11.88		
	Increase/Decrease in Liabilities	(78.93)	78.62		
	Changes in Provision	2.24	0.20		
	Cash Generated from Operations	1,058.85	483.66		
	Direct taxes paid / (refund)	(33.41)	(101.40		
	Net Cash from Operating Activities	1,025.44	382.26		
	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Fixed Assets including Capital Work in Progress	(2.37)	(3.24		
	Investment Expenses	(0.04)	(0.04		
	Interest Received	2.57	0.60		
	Net Cash Used in Investing Activity	0.16	(2.68		
	CASH FLOW FROM FINANCING ACTIVITIES				
	Net (Decrease)/ Increase in Short Term Borrowings	(250.30)	(329.11		
	Interest Paid	(10.89)	(20.06		
	Net Cash Used in Financing Activity	(261.19)	(349.17		
	NET CHANGES IN CASH & CASH EQUIVALENTS (A+B+C)	764.41	30.41		
	OPENING BALANCE OF CASH & CASH EQUIVALENTS	55.31	24.90		
	CLOSING BALANCE OF CASH & CASH EQUIVALENTS	819.72	55.31		

Notes:

 The above audited financial results of the Company for the quarter and year ended March 31, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on June 29, 2021



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544 TRIO

2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).

- 3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant
- (4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
- 5) The figure for quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
- 6) The Company's operations for the financial year have been impacted by the lockdown imposed to contain the spread of Covid-19. The Management of the Company has assessed the impact of the pandemic on its financial results/position such as trade receivables, investments, inventories, trade payables and based on its best judgement and reasonable estimate, has concluded that there are no material adjustments required in the Financial Statements. However the impact assessment of Covid-19 is a continuous process, given the uncertainties associated with its duration and nature, it is not possible to estimate the future impact as at the date of approval of this financial statement. The Company continues to monitor the economic effects of the pandemic while taking steps to improve its execution efficiencies and the financial outcome.
- 7) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 8) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIN: 00312369

**DIRECTOR & CEO** 

Place: Mumbai Dated: 29th June, 2021



9

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, <u>PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657</u> E-mall: info@amphray.com Website: www.triochemproducts.com



Corporate Identity Number: L24249MH1972PLC015544

#### TRIOCHEM PRODUCTS LIMITED Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001 website: www.triochemproducts.com CIN: L24249MH1972PLC015544 (Rs. in lakhs - except otherwise stated) Extract of statement of Audited Financial Results for the Quarter and Year Ended 31st March, 2021 Sr Particulars For the For the For the For the For the Year Ended Year Ended Quarter Quarter Quarter No Ended on Ended on Ended on on on 31-Mar-21 31-Dec-20 31-Mar-20 31-Mar-21 31-Mar-20 Audited Unaudited Unaudited Audited Audited 781.02 394.66 1,407.22 Total Income from operations 1,181.04 2,049.81 1 2 Net Profit / (Loss) for the period (before Tax, (6.04)(9.60)285.48 455.18 (58.11)Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period before tax (after 3 (6.04)(9.60)285.48 (58.11)455.18 Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period after tax (after 4 (5.59)(7.18)212.80 (44.70)340.28 Exceptional and / or Extraordinary items) 5 Total Comprehensive Income for the period (1.36)0.32 0.02 (1.75)(0.22)[Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] Equity share capital (Face value Rs. 10/- per share) 24.50 24.50 24.50 24.50 6 24.50 Other Equity 1,146.69 1,193.14 Earnings per share (of Rs.10/- each) (for continuing and 8 discontinued operations) a) Basic (not annualized) (2.28)(2.93)86.86 138.89 (18.25)b) Diluted (not annualized) (2.28)(2.93)86.86 (18.25)138.89 Notes:

1) The above audited financial results of the Company for the quarter and year ended March 31, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on June 29, 2021.

2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act,2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).

3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant.

4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.

5) The figure for quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: 1.24249MH1972PLC015544



- 6) The Company's operations for the financial year have been impacted by the lockdown imposed to contain the spread of Covid-19. The Management of the Company has assessed the impact of the pandemic on its financial results/position such as trade receivables, investments, inventories, trade payables and based on its best judgement and reasonable estimate, has concluded that there are no material adjustments required in the Financial Statements. However the impact assessment of Covid-19 is a continuous process, given the uncertainties associated with its duration and nature, it is not possible to estimate the future impact as at the date of approval of this financial statement. The Company continues to monitor the economic effects of the pandemic while taking steps to improve its execution efficiencies and the financial outcome.
- 7) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 8) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- 9) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

Place: Mumbai Dated: 29th June, 2021

RAMU S. DEORA **DIRECTOR & CEO** DIN: 00312369

